When did Rapport Therapeutics, Inc. report Q4 2024 earnings?

Rapport Therapeutics, Inc. (RAPP) reported Q4 2024 earnings on March 11, 2025 before market open.

What were Rapport Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Rapport Therapeutics, Inc. reported diluted EPS of $-0.57 for Q4 2024.

Did Rapport Therapeutics, Inc. beat estimates in Q4 2024?

EPS beat the consensus estimate of $-0.62 by $0.05.

Where can I find Rapport Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-036828) directly on SEC EDGAR. The filing index links above go to sec.gov.

Rapport Therapeutics, Inc. RAPP Q4 2024 Annual earnings

Reported March 11, 2025 · Before market open

Diluted EPS-$0.57Beat by $0.05

EPS estimate-$0.62

Next report

Aug 6, 2026 (in a month)

Revenue estimate$2.2M

EPS estimate-$0.96

Financials

Q4 2024

Income statement

See full

Operating income-$23.5M-59.0%

Net income-$20.0M-47.8%

EPS (diluted)-$0.12+98.6%

Balance sheet

See full

Cash & equivalents$56.8M-19.0%

Total debt$1.5M-31.2%

Total equity$305.4M+1,291%

Total assets$314.9M+103%

Cash flow

See full

Operating cash flow-$14.4M-39.5%

CapEx$226.0K-84.3%

Free cash flow-$14.7M-24.4%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$648.87M—

Enterprise value$593.54M—

Returns & leverage

See full

Debt / equity0×—

Current ratio35.3×+18.2×

Versus estimates

Revenue

Q1 2026$20.0MBeat by $12.5M

Diluted EPS

Q1 2026-$0.42Beat by $0.14 Q4 2025-$0.72Miss by $0.07 Q3 2025-$0.71Beat by $0.06 Q2 2025-$0.75Beat by $0.12 Q1 2025-$0.68Beat by $0.09

Q4 2024-$0.57Beat by $0.05

Ask the moment Rapport Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Rapport Therapeutics, Inc. report Q4 2024 earnings?: Rapport Therapeutics, Inc. (RAPP) reported Q4 2024 earnings on March 11, 2025 before market open.
What were Rapport Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Rapport Therapeutics, Inc. reported diluted EPS of $-0.57 for Q4 2024.
Did Rapport Therapeutics, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.62 by $0.05.
Where can I find Rapport Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-036828) directly on SEC EDGAR. The filing index links above go to sec.gov.